Abstract
Fomepizole is a promising new treatment for preventing liver injury
following paracetamol (acetaminophen) overdose. However, we need robust
clinical trials to be performed to demonstrate its effect on clinical
outcomes that are important to our patients and important to healthcare
providers. Until such trials are performed, the toxicology community
should learn the lessons from the COVID pandemic – potential novel
therapeutic options may be theoretically appealing, but their
effectiveness needs to be assessed in robust clinical trials before they
are used in clinical practice.